<DOC>
	<DOC>NCT01021800</DOC>
	<brief_summary>Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.</brief_summary>
	<brief_title>Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>ECOG performance status 02 at the time of inclusion Following R0 or R1 pancreatic tubular adenocarcinoma resection and adjuvant gemcitabine treatment Pregnancy Less than 3 mths expected survival Serious comorbidity Age above 70 yrs</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Pancreatic tubular adenocarcinoma adjuvant setting</keyword>
</DOC>